-transparent.png){kind=logo}
Twenty-three patients with advanced pancreatic adenocarcinoma were treated with Pibenzimol utilizing a daily intravenous schedule for five days. There were no objective responses seen. The major toxicity was pancreatic with grade 3 hyperglycemia in eleven patients. Pibenzimol is inactive in patients with advanced pancreatic adenocarcinoma.
Related Publications
E H Kraut, and
T Fleming, and
M Segal, and
J A Neidhart, and
B C Behrens, and
J MacDonald
April 1986,
Cancer treatment reports,
E H Kraut, and
T Fleming, and
M Segal, and
J A Neidhart, and
B C Behrens, and
J MacDonald
November 1984,
Cancer treatment reports,
E H Kraut, and
T Fleming, and
M Segal, and
J A Neidhart, and
B C Behrens, and
J MacDonald
December 1987,
Cancer treatment reports,
E H Kraut, and
T Fleming, and
M Segal, and
J A Neidhart, and
B C Behrens, and
J MacDonald
February 1990,
Investigational new drugs,
E H Kraut, and
T Fleming, and
M Segal, and
J A Neidhart, and
B C Behrens, and
J MacDonald
October 2005,
Investigational new drugs,
E H Kraut, and
T Fleming, and
M Segal, and
J A Neidhart, and
B C Behrens, and
J MacDonald
January 1981,
Cancer treatment reports,
E H Kraut, and
T Fleming, and
M Segal, and
J A Neidhart, and
B C Behrens, and
J MacDonald
February 1990,
Investigational new drugs,
E H Kraut, and
T Fleming, and
M Segal, and
J A Neidhart, and
B C Behrens, and
J MacDonald
May 1990,
Investigational new drugs,
E H Kraut, and
T Fleming, and
M Segal, and
J A Neidhart, and
B C Behrens, and
J MacDonald
July 1976,
Cancer,
E H Kraut, and
T Fleming, and
M Segal, and
J A Neidhart, and
B C Behrens, and
J MacDonald
January 1983,
Cancer treatment reports,
